Charming Medical Limited Class A Ordinary Shares(MCTA)Earnings, Financials & Key Ratios
MCTA•NASDAQ
414.5× P/E·Price updated Apr 24, 2026
AboutCharming Medical Limited, through its subsidiaries, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. Its services includes womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, traditional Chinese medicine (TCM)-inspired prenatal massage, and Indonesian traditional abdominal binding. The company also provides TCM-inspired supplements products, which includes Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets; and beauty products, including ginseng soothing anti-allergy moisturizing wash for skin issues, and scalp health. In addition, it offers consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. Further, the company's products are used for the treatment of alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, uterine health, enhance physical weakness, balance endocrine functions, and other common women's health issues. it operates wellness centres. The company was founded in 2016 and is headquartered in Causeway Bay, Hong Kong.Show more
- Revenue$6M+3.4%
- EBITDA$2M+18.0%
- Net Income$1M+54.2%
- EPS (Diluted)0.07+54.2%
- Gross Margin67.19%+3.3%
- EBITDA Margin26.56%+14.1%
- Operating Margin22.32%+33.1%
- Net Margin19.27%+49.0%
- ROE2435.04%
MCTA Key Insights
Charming Medical Limited Class A Ordinary Shares (MCTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 2435.0%
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗High debt to equity ratio of 23.6x
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Expensive at 9999.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MCTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MCTA Price & Volume
Charming Medical Limited Class A Ordinary Shares (MCTA) stock price & volume — 10-year historical chart
Loading chart...
MCTA Growth Metrics
Charming Medical Limited Class A Ordinary Shares (MCTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years341.03%
5 Years341.03%
3 Years341.03%
Last Year341.03%
MCTA Peer Comparison
Charming Medical Limited Class A Ordinary Shares (MCTA) competitors in Virtual and consumer health clinics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CANG | 120.56M | 0.31 | -0.19 | 498.08% | -91.96% | -60.5% | 1.41 | |
 CLOV | 2.59B | 5.00 | -29.41 | 40.34% | -2.58% | -17.08% | ||
 ACMR | 7.28B | 109.87 | 80.20 | 15.24% | 9.48% | 5.13% | 0.16 | |
 BTBT | 706.64M | 2.17 | -7 | -30.65% | -146.01% | -0.11% | 0.16 | |
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 CODA | 112.81M | 10.00 | 27.03 | 30.75% | 17.66% | 8.33% | 0.01 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare MCTA vs Peers
Charming Medical Limited Class A Ordinary Shares (MCTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MCTA Income Statement
Charming Medical Limited Class A Ordinary Shares (MCTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
Sales/Revenue | 3.53M | 6.02M | 6.22M |
Revenue Growth % | - | 70.37% | 3.43% |
Cost of Goods Sold | 2.04M | 2.1M | 2.04M |
COGS % of Revenue | 57.69% | 34.93% | 32.81% |
Gross Profit | 1.49M▲ 0% | 3.91M▲ 162.0% | 4.18M▲ 6.8% |
Gross Margin % | 42.31% | 65.07% | 67.19% |
Gross Profit Growth % | - | 162% | 6.81% |
Operating Expenses | 2.02M | 2.91M | 2.79M |
OpEx % of Revenue | 57.07% | 48.3% | 44.87% |
Selling, General & Admin | 1.66M | 2.35M | 2.32M |
SG&A % of Revenue | 47.07% | 39.06% | 37.25% |
Research & Development | 0 | 0 | 0 |
R&D % of Revenue | - | - | - |
Other Operating Expenses | 353.39K | 555.41K | 474.14K |
Operating Income | -521.34K▲ 0% | 1.01M▲ 293.5% | 1.39M▲ 37.7% |
Operating Margin % | -14.77% | 16.77% | 22.32% |
Operating Income Growth % | - | 293.51% | 37.68% |
EBITDA | -310.26K | 1.4M | 1.65M |
EBITDA Margin % | -8.79% | 23.28% | 26.56% |
EBITDA Growth % | - | 551.42% | 17.98% |
D&A (Non-Cash Add-back) | 211.08K | 391.7K | 263.45K |
EBIT | -400.21K | 1.03M | 1.46M |
Net Interest Income | -152.28K | -170.25K | -167.43K |
Interest Income | 10.29K | 19.51K | 64.14K |
Interest Expense | 20.26K | 26.05K | 20.87K |
Other Income/Expense | 100.87K | -5.35K | 46.23K |
Pretax Income | -420.47K▲ 0% | 1M▲ 338.7% | 1.44M▲ 43.0% |
Pretax Margin % | -11.91% | 16.68% | 23.07% |
Income Tax | -84.86K | 181.75K | 236.08K |
Effective Tax Rate % | 20.18% | 18.11% | 16.45% |
Net Income | -305.12K▲ 0% | 777.81K▲ 354.9% | 1.2M▲ 54.2% |
Net Margin % | -8.64% | 12.93% | 19.27% |
Net Income Growth % | - | 354.92% | 54.16% |
Net Income (Continuing) | -335.61K | 821.74K | 1.2M |
Discontinued Operations | 0 | 0 | 0 |
Minority Interest | -110.21K | -66.63K | 0 |
EPS (Diluted) | -0.02▲ 0% | 0.05▲ 355.0% | 0.07▲ 54.2% |
EPS Growth % | - | 355% | 54.25% |
EPS (Basic) | -0.02 | 0.05 | 0.07 |
Diluted Shares Outstanding | 16.94M | 16.94M | 16.94M |
Basic Shares Outstanding | 16.94M | 16.94M | 16.94M |
Dividend Payout Ratio | - | - | - |
MCTA Balance Sheet
Charming Medical Limited Class A Ordinary Shares (MCTA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
Total Current Assets | 4.12M | 3.67M | 3.37M |
Cash & Short-Term Investments | 1.93M | 2.1M | 2.76M |
Cash Only | 1.93M | 2.1M | 816.77K |
Short-Term Investments | 0 | 0 | 1.94M |
Accounts Receivable | 2.12M | 1.54M | 579.09K |
Days Sales Outstanding | 219.61 | 93.18 | 33.97 |
Inventory | 66.33K | 28.15K | 26.8K |
Days Inventory Outstanding | 11.89 | 4.89 | 4.79 |
Other Current Assets | 0 | 0 | 0 |
Total Non-Current Assets | 2.26M | 1.21M | 1.99M |
Property, Plant & Equipment | 1.8M | 921.86K | 1.21M |
Fixed Asset Turnover | 1.96x | 6.53x | 5.14x |
Goodwill | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 |
Other Non-Current Assets | 193.75K | 81.44K | 700.64K |
Total Assets | 6.38M▲ 0% | 4.88M▼ 23.5% | 5.36M▲ 9.7% |
Asset Turnover | 0.55x | 1.23x | 1.16x |
Asset Growth % | - | -23.53% | 9.71% |
Total Current Liabilities | 7.17M | 5.88M | 4.95M |
Accounts Payable | 1.57K | 0 | 3.48K |
Days Payables Outstanding | 0.28 | - | 0.62 |
Short-Term Debt | 589.66K | 442.61K | 314.23K |
Deferred Revenue (Current) | 5.6M | 4.5M | 3.46M |
Other Current Liabilities | 0 | 0 | 0 |
Current Ratio | 0.57x | 0.62x | 0.68x |
Quick Ratio | 0.57x | 0.62x | 0.68x |
Cash Conversion Cycle | 231.21 | - | 38.14 |
Total Non-Current Liabilities | 484.26K | 148.25K | 358.03K |
Long-Term Debt | 0 | 0 | 0 |
Capital Lease Obligations | 484.26K | 148.25K | 358.03K |
Deferred Tax Liabilities | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 |
Total Liabilities | 7.65M | 6.03M | 5.31M |
Total Debt | 1.81M | 961.38K | 1.16M |
Net Debt | -119.68K | -1.14M | 343.87K |
Debt / Equity | - | - | 23.57x |
Debt / EBITDA | - | 0.69x | 0.70x |
Net Debt / EBITDA | - | -0.82x | 0.21x |
Interest Coverage | -25.73x | 38.73x | 66.54x |
Total Equity | -1.27M▲ 0% | -1.15M▲ 9.7% | 49.24K▲ 104.3% |
Equity Growth % | - | 9.67% | 104.3% |
Book Value per Share | -0.07 | -0.07 | 0.00 |
Total Shareholders' Equity | -1.16M | -1.08M | 49.24K |
Common Stock | 1.53K | 1.53K | 1.53K |
Retained Earnings | -1.16M | -1.08M | 119.44K |
Treasury Stock | 0 | 0 | 0 |
Accumulated OCI | 3.92K | 205 | -3.57K |
Minority Interest | -110.21K | -66.63K | 0 |
MCTA Cash Flow Statement
Charming Medical Limited Class A Ordinary Shares (MCTA) cash flow — operating, investing & free cash flow history
| Metric | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
Cash from Operations | 2.43M | 295.43K | 425.89K |
Operating CF Margin % | 68.93% | 4.91% | 6.85% |
Operating CF Growth % | - | -87.86% | 44.16% |
Net Income | -335.61K | 821.74K | 1.2M |
Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
Stock-Based Compensation | 0 | 0 | 0 |
Deferred Taxes | 0 | 62.48K | 134.87K |
Other Non-Cash Items | 60.9K | -37.45K | -10.89K |
Working Capital Changes | 2.5M | -943.05K | -1.16M |
Change in Receivables | -154.02K | -164.98K | -44.29K |
Change in Inventory | -55.87K | 38.18K | 1.35K |
Change in Payables | 180.4K | 210.28K | -204.69K |
Cash from Investing | -606.19K | -210.6K | -2.23M |
Capital Expenditures | -606.19K | -210.6K | -287.53K |
CapEx % of Revenue | 17.17% | 3.5% | 4.62% |
Acquisitions | 0 | 0 | 0 |
Investments | - | - | - |
Other Investing | 0 | 0 | 0 |
Cash from Financing | -1.43M | 100.14K | 521.3K |
Debt Issued (Net) | -177.92K | -115.85K | 48.93K |
Equity Issued (Net) | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 |
Other Financing | -1.25M | 216K | 472.37K |
Net Change in Cash | 402.99K▲ 0% | 174.46K▼ 56.7% | -1.29M▼ 837.6% |
Free Cash Flow | 1.83M▲ 0% | 84.83K▼ 95.4% | 138.36K▲ 63.1% |
FCF Margin % | 51.76% | 1.41% | 2.22% |
FCF Growth % | - | -95.36% | 63.1% |
FCF per Share | 0.11 | 0.01 | 0.01 |
FCF Conversion (FCF/Net Income) | -7.98x | 0.38x | 0.36x |
Interest Paid | 20.26K | 26.05K | 20.87K |
Taxes Paid | 0 | 0 | 0 |
MCTA Key Ratios
Charming Medical Limited Class A Ordinary Shares (MCTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
Return on Equity (ROE) | - | - | 2435.04% |
Return on Invested Capital (ROIC) | - | - | 264.99% |
Gross Margin | 42.31% | 65.07% | 67.19% |
Net Margin | -8.64% | 12.93% | 19.27% |
Debt / Equity | - | - | 23.57x |
Interest Coverage | -25.73x | 38.73x | 66.54x |
FCF Conversion | -7.98x | 0.38x | 0.36x |
Revenue Growth | - | 70.37% | 3.43% |
Related:MCTA Dividend History·MCTA Revenue History·MCTA Price History·MCTA P/E History·MCTA Financial Ratios·MCTA Institutional Holders
MCTA Frequently Asked Questions
Charming Medical Limited Class A Ordinary Shares (MCTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Charming Medical Limited Class A Ordinary Shares (MCTA) reported $6.2M in revenue for fiscal year 2024. This represents a 76% increase from $3.5M in 2022.
Charming Medical Limited Class A Ordinary Shares (MCTA) grew revenue by 3.4% over the past year. Growth has been modest.
Yes, Charming Medical Limited Class A Ordinary Shares (MCTA) is profitable, generating $1.2M in net income for fiscal year 2024 (19.3% net margin).
Dividend & Returns
Charming Medical Limited Class A Ordinary Shares (MCTA) has a return on equity (ROE) of 2435.0%. This is excellent, indicating efficient use of shareholder capital.
Charming Medical Limited Class A Ordinary Shares (MCTA) generated $0.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.